O Passo a Passo do Diagnóstico da Insuficiencia Cardíaca com Fração de Ejeção Preservada (ICFEp)


Referências
1. Iyngkaran P, Thomas MC, Neil C, Jelinek M, Cooper M, Horowitz JD, et al. The heart failure with preserved ejection fraction conundrum-redefining the problem and finding common ground? Curr Heart Fail Rep. 2020;17(2):34-42. 2. Escobar C, Palacios B, Varela L, Gutiérrez M, Duong M, Chen H, et al. Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Serv Res. 2022;22(1):1241. 3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chroni.c heart failure. Eur Heart J 2021, 42(36):3599-726 4. Komajda M. Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eurv Heart J. 2014;35(16):1022-32. 5. Marcondes-Braga FG, Moura LAZ, Issa VS, Vieira JL, Rohde LE, Simões MV, et al. Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021 Arq Bras Cardiol. 2021;116(6):1174-212 6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. 7. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Medm 2022;387(12):1089-98 8. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. 9. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. 10. Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, et al. 2023 ACC. Expert consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023,81(18):1835-78.ENTRESTO®
sacubitril valsartana sódica hidratada
VIA ORAL
Clique para ler a bula de Entresto® na íntegra.
Contraindicações:Em doentes com história de angioedema relacionado à terapia anterior com inibidor da ECA ou BRA; utilização concomitante de inibidores da ECA. Não administrar dentro de 36 horas após a descontinuação da terapia com inibidor da ECA.
Interações Medicamentosas: O uso concomitante de Entresto® com um inibidor da ECA está contraindicado devido ao risco aumentado de angioedema.
BR-29584